JP2010540625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540625A5 JP2010540625A5 JP2010527915A JP2010527915A JP2010540625A5 JP 2010540625 A5 JP2010540625 A5 JP 2010540625A5 JP 2010527915 A JP2010527915 A JP 2010527915A JP 2010527915 A JP2010527915 A JP 2010527915A JP 2010540625 A5 JP2010540625 A5 JP 2010540625A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- cancer
- group
- substituted
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 12
- -1 substituted Chemical class 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 230000007170 pathology Effects 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 3
- 102100030011 Endoribonuclease Human genes 0.000 claims 3
- 101710199605 Endoribonuclease Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 claims 3
- 206010047642 Vitiligo Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006143 Brain stem glioma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010028561 Myeloid metaplasia Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 208000021161 Plasma cell disease Diseases 0.000 claims 2
- 208000037062 Polyps Diseases 0.000 claims 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 201000011186 acute T cell leukemia Diseases 0.000 claims 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 210000002768 hair cell Anatomy 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000004804 Adenomatous Polyps Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000010000 Agranulocytosis Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008263 Cervical dysplasia Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 claims 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 206010042276 Subacute endocarditis Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000028183 atypical endometrial hyperplasia Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000003385 seborrheic keratosis Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97772007P | 2007-10-05 | 2007-10-05 | |
| US60/977,720 | 2007-10-05 | ||
| US7553208P | 2008-06-25 | 2008-06-25 | |
| US61/075,532 | 2008-06-25 | ||
| PCT/SG2008/000379 WO2009045175A1 (en) | 2007-10-05 | 2008-10-03 | Pyrimidine substituted purine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013253369A Division JP5885729B2 (ja) | 2007-10-05 | 2013-12-06 | ピリミジン置換プリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540625A JP2010540625A (ja) | 2010-12-24 |
| JP2010540625A5 true JP2010540625A5 (enExample) | 2011-12-01 |
| JP5479346B2 JP5479346B2 (ja) | 2014-04-23 |
Family
ID=40030252
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527915A Expired - Fee Related JP5479346B2 (ja) | 2007-10-05 | 2008-10-03 | ピリミジン置換プリン誘導体 |
| JP2013253369A Expired - Fee Related JP5885729B2 (ja) | 2007-10-05 | 2013-12-06 | ピリミジン置換プリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013253369A Expired - Fee Related JP5885729B2 (ja) | 2007-10-05 | 2013-12-06 | ピリミジン置換プリン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8247410B2 (enExample) |
| EP (1) | EP2209786B1 (enExample) |
| JP (2) | JP5479346B2 (enExample) |
| KR (3) | KR20160116045A (enExample) |
| CN (2) | CN104119336B (enExample) |
| AU (1) | AU2008307798B2 (enExample) |
| BR (1) | BRPI0817503B8 (enExample) |
| CA (1) | CA2701581C (enExample) |
| DK (1) | DK2209786T3 (enExample) |
| ES (1) | ES2406129T3 (enExample) |
| IL (2) | IL204804A (enExample) |
| MX (1) | MX2010003668A (enExample) |
| MY (1) | MY150993A (enExample) |
| RU (2) | RU2681081C2 (enExample) |
| WO (1) | WO2009045175A1 (enExample) |
| ZA (1) | ZA201003118B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
| JP5479346B2 (ja) | 2007-10-05 | 2014-04-23 | ベラステム・インコーポレーテッド | ピリミジン置換プリン誘導体 |
| MX340204B (es) | 2008-04-11 | 2016-06-30 | Emergent Product Dev Seattle | Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo. |
| WO2010005558A2 (en) * | 2008-07-07 | 2010-01-14 | Xcovery, Inc. | Pi3k isoform selective inhibitors |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| KR20110098908A (ko) * | 2008-11-11 | 2011-09-02 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | ＰＩ3Ｋ/ｍＴＯＲ 키나제 억제제 |
| EP2411387B1 (en) | 2009-03-27 | 2015-08-19 | VetDC, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| CA2757485C (en) | 2009-04-03 | 2017-01-17 | Dizhong Chen | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
| WO2010114494A1 (en) * | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders |
| TW201105662A (en) | 2009-07-07 | 2011-02-16 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| DE102009049679A1 (de) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| WO2011078795A1 (en) * | 2009-12-21 | 2011-06-30 | S*Bio Pte Ltd | Bridged morpholino substituted purines |
| ES2685171T3 (es) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramación de células a un nuevo destino |
| EP2691384B1 (en) | 2011-03-28 | 2016-10-26 | MEI Pharma, Inc. | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
| WO2012172043A1 (en) | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| CA2857601A1 (en) * | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| TW201410657A (zh) | 2012-08-02 | 2014-03-16 | Endo Pharmaceuticals Inc | 經取代胺基－嘧啶衍生物 |
| KR101982912B1 (ko) * | 2013-10-16 | 2019-09-10 | 상하이 잉리 파마슈티컬 컴퍼니 리미티드 | 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도 |
| GB201321737D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| ES2713196T3 (es) | 2013-12-11 | 2019-05-20 | Biogen Ma Inc | Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología |
| PT3080103T (pt) * | 2013-12-11 | 2018-07-23 | Sunesis Pharmaceuticals Inc | Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia |
| WO2016109426A1 (en) * | 2014-12-29 | 2016-07-07 | Verastem, Inc. | Oral dosing regimen of a dual mtor and pi3 inhibitor |
| CN105985354B (zh) * | 2015-02-09 | 2020-10-02 | 南京盖特医药技术有限公司 | 嘧啶衍生物、细胞毒性剂、药物组合物及其应用 |
| HRP20190998T1 (hr) | 2015-03-30 | 2019-10-18 | Daiichi Sankyo Company, Limited | 6-morfolinil-2-pirazolil-9h-purinski derivati i njihova primjena kao p13k inhibitora |
| KR101589900B1 (ko) | 2015-07-30 | 2016-01-29 | 강영만 | 바닥설치용 경계구 |
| JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| CN109476696B (zh) * | 2016-06-02 | 2022-06-10 | 细胞基因公司 | 动物及人抗锥虫和抗利什曼原虫剂 |
| CN109311843B (zh) * | 2016-06-16 | 2021-10-08 | 詹森药业有限公司 | 作为PI3Kβ抑制剂的氮杂苯并咪唑衍生物 |
| ES2911522T3 (es) | 2016-12-02 | 2022-05-19 | Daiichi Sankyo Co Ltd | Novedosa endo-ß-n-acetilglucosaminidasa |
| WO2018178944A1 (en) * | 2017-03-31 | 2018-10-04 | Ftg Bio Llc | Salt forms of amino pyrazine purine based selective kinase inhibitor |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| CN110996959A (zh) | 2017-05-23 | 2020-04-10 | 梅制药公司 | 联合疗法 |
| EP3668507A4 (en) | 2017-08-14 | 2021-05-12 | MEI Pharma, Inc. | Combination therapy |
| CA3114260A1 (en) * | 2018-09-27 | 2020-04-02 | Shanghai Yingli Pharmaceutical Co., Ltd | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof |
| MX2021007179A (es) | 2018-12-20 | 2021-09-28 | Ksq Therapeutics Inc | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1). |
| JP2023548148A (ja) | 2020-10-30 | 2023-11-15 | ケーエスキュー セラピューティクス， インコーポレイテッド | 置換ピラゾロピリミジンの固体形態及びその使用 |
| WO2024041519A1 (zh) * | 2022-08-24 | 2024-02-29 | 上海璎黎药业有限公司 | 一种吗啉基喹唑啉类化合物、其药物组合物及应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617304A (en) * | 1984-04-10 | 1986-10-14 | Merck & Co., Inc. | Purine derivatives |
| US4772606A (en) * | 1985-08-22 | 1988-09-20 | Warner-Lambert Company | Purine derivatives |
| DE122010000024I1 (de) * | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
| US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5994361A (en) * | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
| TW589309B (en) | 1997-07-03 | 2004-06-01 | Bristol Myers Squibb Pharma Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| NZ506234A (en) * | 1998-02-26 | 2003-05-30 | Aventis Pharma Inc | 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines, pharmaceuticals thereof and their use for inhibiting cdk-2 |
| ES2360933T3 (es) * | 2000-04-27 | 2011-06-10 | Astellas Pharma Inc. | Derivados de heteroarilo condensados. |
| JP3810017B2 (ja) * | 2000-04-27 | 2006-08-16 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| CN100413852C (zh) * | 2000-07-19 | 2008-08-27 | 诺瓦提斯公司 | 缬沙坦的盐 |
| GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| CA2463563A1 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
| GB0219054D0 (en) | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| US20050288503A1 (en) | 2002-09-06 | 2005-12-29 | Adams Jerry L | Novel compounds |
| CA2502356A1 (en) | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Aromatic bicyclic heterocyles to modulate 1l - 12 production |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| ES2412273T3 (es) * | 2002-11-21 | 2013-07-10 | Novartis Ag | Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer. |
| CN1735607B (zh) * | 2002-11-21 | 2010-06-09 | 诺华疫苗和诊断公司 | 2,4,6-三取代的嘧啶作为磷脂酰肌醇(pi)3-激酶抑制剂及其在治疗癌症中的应用 |
| FR2851248B1 (fr) * | 2003-02-18 | 2005-04-08 | Aventis Pharma Sa | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| JP5321061B2 (ja) | 2005-08-11 | 2013-10-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 不飽和複素環誘導体 |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| GB0519245D0 (en) | 2005-09-20 | 2005-10-26 | Vernalis R&D Ltd | Purine compounds |
| US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| JP5479346B2 (ja) | 2007-10-05 | 2014-04-23 | ベラステム・インコーポレーテッド | ピリミジン置換プリン誘導体 |
| WO2009045174A1 (en) * | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| TW200938201A (en) | 2008-02-07 | 2009-09-16 | Chugai Pharmaceutical Co Ltd | Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof |
| AU2009251291B2 (en) * | 2008-05-30 | 2013-05-02 | F. Hoffmann-La Roche Ag | Purine PI3K inhibitor compounds and methods of use |
| WO2009157880A1 (en) * | 2008-06-27 | 2009-12-30 | S*Bio Pte Ltd | Pyrazine substituted purines |
| WO2010005558A2 (en) | 2008-07-07 | 2010-01-14 | Xcovery, Inc. | Pi3k isoform selective inhibitors |
| CA2757485C (en) | 2009-04-03 | 2017-01-17 | Dizhong Chen | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
| WO2010114494A1 (en) | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders |
-
2008
- 2008-10-03 JP JP2010527915A patent/JP5479346B2/ja not_active Expired - Fee Related
- 2008-10-03 MY MYPI20101500 patent/MY150993A/en unknown
- 2008-10-03 BR BRPI0817503A patent/BRPI0817503B8/pt not_active IP Right Cessation
- 2008-10-03 MX MX2010003668A patent/MX2010003668A/es active IP Right Grant
- 2008-10-03 KR KR1020167026687A patent/KR20160116045A/ko not_active Withdrawn
- 2008-10-03 WO PCT/SG2008/000379 patent/WO2009045175A1/en not_active Ceased
- 2008-10-03 AU AU2008307798A patent/AU2008307798B2/en not_active Ceased
- 2008-10-03 DK DK08836404.7T patent/DK2209786T3/da active
- 2008-10-03 CN CN201410185174.XA patent/CN104119336B/zh not_active Expired - Fee Related
- 2008-10-03 US US12/681,584 patent/US8247410B2/en not_active Expired - Fee Related
- 2008-10-03 KR KR1020107009977A patent/KR101643237B1/ko not_active Expired - Fee Related
- 2008-10-03 RU RU2014110894A patent/RU2681081C2/ru not_active IP Right Cessation
- 2008-10-03 EP EP08836404A patent/EP2209786B1/en not_active Not-in-force
- 2008-10-03 CN CN200880119649.8A patent/CN101889015B/zh not_active Expired - Fee Related
- 2008-10-03 RU RU2010117737/04A patent/RU2518098C2/ru not_active IP Right Cessation
- 2008-10-03 KR KR1020157013280A patent/KR101701109B1/ko not_active Expired - Fee Related
- 2008-10-03 ES ES08836404T patent/ES2406129T3/es active Active
- 2008-10-03 CA CA2701581A patent/CA2701581C/en not_active Expired - Fee Related
-
2010
- 2010-03-28 IL IL204804A patent/IL204804A/en active IP Right Grant
- 2010-05-04 ZA ZA2010/03118A patent/ZA201003118B/en unknown
-
2012
- 2012-07-20 US US13/554,491 patent/US8609838B2/en not_active Expired - Fee Related
-
2013
- 2013-11-11 US US14/076,810 patent/US20140066620A1/en not_active Abandoned
- 2013-12-06 JP JP2013253369A patent/JP5885729B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-06 IL IL235555A patent/IL235555B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540625A5 (enExample) | ||
| RU2010117737A (ru) | Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ, и способ лечения пролиферативных заболеваний | |
| ES2733576T3 (es) | Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas | |
| JP2023519815A (ja) | スピロ環含有キナゾリン化合物 | |
| AU2012274160B2 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| RU2011141792A (ru) | Пиримидинзамещенные пуриновые соединения в качестве ингибиторов киназы ( или киназ ) | |
| ES2746850T3 (es) | Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado | |
| ES2586124T3 (es) | Polimorfo de rifaximina y proceso para la preparación del mismo | |
| AU2016276426B2 (en) | Polymorphic forms of Afatinib free base and Afatinib dimaleate | |
| CA2575720A1 (en) | Pyrimidine derivatives | |
| AU2013207712A1 (en) | Heterocyclic compounds and uses as anticancer agents. | |
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| JP2016033166A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物 | |
| WO2017152706A1 (zh) | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 | |
| CN108290882B (zh) | 用于治疗呼吸道合胞病毒感染的4-喹唑啉胺衍生物的晶形 | |
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| JP2015515995A (ja) | キナーゼ阻害剤として有用な置換アミノキナゾリン | |
| JP2018521969A (ja) | 医薬用共結晶及びその用途 | |
| CN106660970A (zh) | 喹唑啉衍生物 | |
| JP2009508876A5 (enExample) | ||
| JP7622986B2 (ja) | （Ｓ）－２－アミノ－３－｛４－［（５－アミノ－２－フェニルベンゾ［ｄ］オキサゾール－７－イル）メトキシ］－３，５－ジクロロフェニル｝プロパン酸・１塩酸塩、その１水和物、およびその結晶とその製造方法 | |
| CN113788826B (zh) | 共晶体 | |
| WO2015098855A1 (ja) | ピラジノ［２，１－ｃ］［１，２，４］トリアジン化合物の結晶（２） | |
| JP5651271B2 (ja) | デニブリン二塩酸塩 | |
| AU2022275275A1 (en) | Polymorph of imidazolidinone compound, preparation method therefor and use thereof |